Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
WELL Stock Overview
WELL Health Technologies Corp. operates as a practitioner focused digital health company in Canada, the United States, and internationally.
WELL Health Technologies Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$3.32 |
52 Week High | CA$8.86 |
52 Week Low | CA$3.04 |
Beta | 1.31 |
1 Month Change | -12.63% |
3 Month Change | -33.07% |
1 Year Change | -59.31% |
3 Year Change | 260.87% |
5 Year Change | 1,560.00% |
Change since IPO | 2,041.94% |
Recent News & Updates
WELL Health Technologies Corp.'s (TSE:WELL) Intrinsic Value Is Potentially 43% Above Its Share Price
How far off is WELL Health Technologies Corp. ( TSE:WELL ) from its intrinsic value? Using the most recent financial...
Shareholder Returns
WELL | CA Healthcare | CA Market | |
---|---|---|---|
7D | 4.7% | 3.4% | 0.3% |
1Y | -59.3% | -33.7% | -4.0% |
Return vs Industry: WELL underperformed the Canadian Healthcare industry which returned -33.7% over the past year.
Return vs Market: WELL underperformed the Canadian Market which returned -4% over the past year.
Price Volatility
WELL volatility | |
---|---|
WELL Average Weekly Movement | 8.1% |
Healthcare Industry Average Movement | 8.5% |
Market Average Movement | 10.0% |
10% most volatile stocks in CA Market | 17.3% |
10% least volatile stocks in CA Market | 4.4% |
Stable Share Price: WELL is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: WELL's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 1,507 | Hamed Shahbazi | https://www.well.company |
WELL Health Technologies Corp. operates as a practitioner focused digital health company in Canada, the United States, and internationally. It offers end-to-end omni-channel patient services, including primary care; physiotherapy, occupational therapy, chiropractic, dietary, mental health counselling, and sleep related services; specialized care, including gastroenterologists; diagnostic services related to cardiology, women’s health, and bone/muscle health and cancer diagnostics; and telehealth services. The company also operates OSCAR Pro, an electronic medical records platform; telehealth platforms, including Tia Health, VirtualClinic+, VirtuelMed, Adracare, and Circle Medical; Apps.health, a digital health app marketplace; Insig, which offers virtual care and digital patient engagement services; billing and revenue cycle management solutions for billing and back-office services comprising billing-as-a-service outsourcing services to doctors; and cybersecurity protection and patient data privacy solutions.
WELL Health Technologies Fundamentals Summary
WELL fundamental statistics | |
---|---|
Market Cap | CA$738.01m |
Earnings (TTM) | -CA$44.33m |
Revenue (TTM) | CA$403.27m |
1.8x
P/S Ratio-16.6x
P/E RatioIs WELL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
WELL income statement (TTM) | |
---|---|
Revenue | CA$403.27m |
Cost of Revenue | CA$190.23m |
Gross Profit | CA$213.04m |
Other Expenses | CA$257.38m |
Earnings | -CA$44.33m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.20 |
Gross Margin | 52.83% |
Net Profit Margin | -10.99% |
Debt/Equity Ratio | 44.7% |
How did WELL perform over the long term?
See historical performance and comparisonValuation
Is WELL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for WELL?
Other financial metrics that can be useful for relative valuation.
What is WELL's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | CA$738.01m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.9x |
Enterprise Value/EBITDA | 20.2x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does WELL's PS Ratio compare to its peers?
WELL PS Ratio vs Peers |
---|
Company | PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2.2x | ||
AND Andlauer Healthcare Group | 3.7x | 5.4% | CA$1.8b |
VMD Viemed Healthcare | 1.9x | 11.1% | CA$289.9m |
DNTL dentalcorp Holdings | 2x | 14.1% | CA$2.0b |
QIPT Quipt Home Medical | 1.3x | 21.8% | CA$196.0m |
WELL WELL Health Technologies | 1.8x | 12.1% | CA$738.0m |
Price-To-Sales vs Peers: WELL is good value based on its Price-To-Sales Ratio (1.8x) compared to the peer average (2.2x).
Price to Earnings Ratio vs Industry
How does WELL's PE Ratio compare vs other companies in the CA Healthcare Industry?
Price-To-Sales vs Industry: WELL is expensive based on its Price-To-Sales Ratio (1.8x) compared to the Canadian Healthcare industry average (1.4x)
Price to Sales Ratio vs Fair Ratio
What is WELL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 1.8x |
Fair PS Ratio | 2.4x |
Price-To-Sales vs Fair Ratio: WELL is good value based on its Price-To-Sales Ratio (1.8x) compared to the estimated Fair Price-To-Sales Ratio (2.4x).
Share Price vs Fair Value
What is the Fair Price of WELL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: WELL (CA$3.32) is trading below our estimate of fair value (CA$5.67)
Significantly Below Fair Value: WELL is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate WELL's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is WELL Health Technologies forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Future Growth Score
1/6Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
120.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: WELL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: WELL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: WELL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: WELL's revenue (12.1% per year) is forecast to grow faster than the Canadian market (6.9% per year).
High Growth Revenue: WELL's revenue (12.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if WELL's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has WELL Health Technologies performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-55.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: WELL is currently unprofitable.
Growing Profit Margin: WELL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: WELL is unprofitable, and losses have increased over the past 5 years at a rate of 55.8% per year.
Accelerating Growth: Unable to compare WELL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WELL is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-68.2%).
Return on Equity
High ROE: WELL has a negative Return on Equity (-3.66%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is WELL Health Technologies's financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: WELL's short term assets (CA$121.0M) do not cover its short term liabilities (CA$149.6M).
Long Term Liabilities: WELL's short term assets (CA$121.0M) do not cover its long term liabilities (CA$387.3M).
Debt to Equity History and Analysis
Debt Level: WELL's net debt to equity ratio (39.6%) is considered satisfactory.
Reducing Debt: WELL had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: WELL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if WELL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Dividend
What is WELL Health Technologies's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate WELL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate WELL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if WELL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if WELL's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as WELL has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
3.2yrs
Average management tenure
CEO
Hamed Shahbazi (46 yo)
4.08yrs
Tenure
CA$5,178,000
Compensation
Mr. Hamed Shahbazi, B.Sc serves as Venture Partner at Pender Ventures, and serves as a Director at Hire Technologies Inc. (formerly known as Bay Talent Group Inc.) (formerly known as Danacore Industries In...
Leadership Team
Experienced Management: WELL's management team is considered experienced (3.2 years average tenure).
Board Members
Experienced Board: WELL's board of directors are considered experienced (4.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: WELL insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.5%.
Top Shareholders
Company Information
WELL Health Technologies Corp.'s employee growth, exchange listings and data sources
Key Information
- Name: WELL Health Technologies Corp.
- Ticker: WELL
- Exchange: TSX
- Founded: 2010
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: CA$738.009m
- Shares outstanding: 222.29m
- Website: https://www.well.company
Number of Employees
Location
- WELL Health Technologies Corp.
- 322 Water Street
- Suite 200
- Vancouver
- British Columbia
- V6B 1B6
- Canada
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/27 00:00 |
End of Day Share Price | 2022/06/27 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.